Ipsen is a global biopharmaceutical company, improving patients’ lives through research and innovation in oncology, rare disease & neuroscience.

Ipsen Icon

Ipsen Logo

Ipsen is a French pharmaceutical company headquartered in Boulogne-Billancourt, France. The company was founded in 1929 by Henri Beaufour and currently operates in more than 30 countries worldwide. It is dedicated to developing innovative therapies to improve the lives of patients suffering from diseases in three main therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen's headquarters in Boulogne-Billancourt serve as the center of its global operations. The facility houses various departments such as research and development, manufacturing, and global marketing. It also includes laboratories for scientific research and development of new drugs. The company's commitment to innovation is evident through its investment in state-of-the-art technology and facilities. Ipsen offers a wide range of pharmaceutical products and services. Its portfolio includes drugs for cancer treatments, such as Somatuline, Decapeptyl, and Cabometyx, as well as solutions for neurological disorders like Dysport and Apokyn. In the rare diseases area, the company provides treatments for conditions like acromegaly, pancreatic insufficiency, and neuroendocrine tumors. Ipsen also offers a variety of support programs and patient-centric services to ensure the best possible patient outcomes. With a global presence, Ipsen operates through a network of subsidiaries, joint ventures, and partnerships. Some notable subsidiaries include Ipsen Biopharmaceuticals in the United States, Ipsen Pharma in Germany, Ipsen Pharma S.A.P.I. Ltd. The company also has several joint ventures and partnerships with organizations like Blueprint Medicines and AKU Society, further expanding its reach and capabilities. In terms of market position, Ipsen is recognized as a global leader in specialty pharmaceuticals. It has a strong presence in Europe, North America, and Asia-Pacific regions. Ipsen's annual revenue in 2020 exceeded €2.5 billion, marking significant growth over the years. The company continually strives to strengthen its market position through partnerships, collaborations, and acquisitions. Ipsen has achieved several milestones and made notable changes to its product lineup and business strategy. In recent years, the company has expanded its focus on rare diseases, investing in research and development of treatments for these underserved patient populations. Ipsen has also emphasized digital platforms and technologies to improve patient care and support services. As of the latest updates, Ipsen continues to demonstrate strong financial performance and expansion. The company remains committed to bringing meaningful innovations to patients worldwide by leveraging its scientific expertise, global presence, and commitment to delivering transformative therapies. In conclusion, Ipsen is a leading French pharmaceutical company with a rich history and extensive global operations. Through its innovative products and dedication to patient care, Ipsen has established itself as a prominent player in the pharmaceutical industry. Its commitment to research, strategic partnerships, and expanding product portfolio positions the company for sustained growth.

Ipsen

Pioneering Diagnostics A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries.

Health

Biotechnology and Pharmaceuticals

Arial

youtube

twitter

linkedin

instagram

facebook

The company was founded in 1963 by Dr. Alain Mérieux, who aimed to improve public health by combating infectious diseases. Initially focused on the development of diagnostic tests for infectious diseases, bioMérieux gradually expanded its product portfolio to cover a wide range of medical conditions. The company offers a comprehensive range of products and services, including automated systems, reagents, instruments, and software solutions for clinical diagnostics, industrial microbiology, and antimicrobial resistance management. Their innovative diagnostic solutions address major public health concerns such as bloodstream infections, respiratory infections, sepsis, or food safety. Operating on a global scale, bioMérieux has established a strong presence in over 160 countries. The company has an extensive network of subsidiaries, joint ventures, and partnerships worldwide. Notable subsidiaries include bioMérieux Inc. Additionally, bioMérieux collaborates with various academic institutions, research organizations, and industry partners to advance medical diagnostics and drive innovation. bioMérieux holds a prominent position in the global market for in vitro diagnostics. The company's annual sales have consistently increased over the years, reaching €2.7 billion in 2020. With a focus on research and development, bioMérieux invests heavily in technological advancements and product innovation, maintaining its competitive edge in the diagnostic industry. The company places a strong emphasis on sustainable development and has implemented eco-friendly initiatives throughout its operations. In recent years, bioMérieux has achieved significant milestones, including the acquisition of pre-analytics specialist Wasatch Microfluidics and the launch of the BioFire Respiratory Panel 2.1, which detects multiple pathogens responsible for respiratory infections. These strategic moves and product developments have enhanced bioMérieux's product lineup and further solidified its position in the market. As of the latest available information, bioMérieux continues to lead the field of IVD and remains committed to addressing global health challenges. The company actively responds to emerging infectious diseases and has played a critical role in the fight against the COVID-19 pandemic, developing diagnostics and supporting testing efforts around the world.

bioMérieux

bioMérieux Icon

bioMérieux Logo

Syngenta

Syngenta AG is part of Syngenta Group, a global agricultural technology company, headquartered in Basel, Switzerland, with over 50,000 employees in more than 90 countries. We create best-in-class solutions to local and global agricultural challenges by accelerating innovation through R&D and AI.Syngenta Group is the world’s largest agricultural technology company by revenue, ranked number one in crop protection, number one in biologicals and number three in seeds. With one of the industry's largest innovation pipelines, we don't just develop breakthrough solutions — we deliver them.

Gosz & Partners, LLP

As the global leader in smart, healthy and sustainable buildings, our mission is to reimagine the performance of buildings to serve people, places & the planet.

Law Enforcement and Protective Services

Law and Government

NotoSansBold

NotoSansRegular

Johnson Controls is a multinational conglomerate headquartered in Milwaukee, Wisconsin, United States. It was founded in 1885 by Warren S. Johnson, who invented and patented the first electric room thermostat. Initially, Johnson Controls operated as a provider of temperature control systems. However, over the years, the company expanded its product offering and diversified its operations. Currently, Johnson Controls specializes in manufacturing and supplying equipment, controls, and services for buildings and vehicles. In terms of building efficiency, Johnson Controls offers a wide range of products and services. These include HVAC (heating, ventilation, and air conditioning) systems, controls, sensors, security systems, fire detection and suppression, and energy management solutions. The company's building efficiency division aims to create sustainable, comfortable, and safe environments across various sectors, including commercial buildings, healthcare facilities, educational institutions, and governmental buildings. Johnson Controls also has a strong presence in the automotive industry. The company provides automotive seating systems, which are innovative, comfortable, and offer enhanced safety features. Additionally, Johnson Controls supplies batteries for hybrid and electric vehicles, as well as advanced technology for vehicle interiors, such as instrument panels, door panels, and overhead systems. On a global scale, Johnson Controls has a significant presence with operations in over 150 countries. The company has multiple subsidiaries and joint ventures, including Adient, which focuses on automotive seating; Tyco International, which specializes in fire and security solutions; and Hitachi Appliances, a joint venture with Hitachi Limited. In the market, Johnson Controls holds a strong position, particularly in the building efficiency sector. The company's global sales reached $22.8 billion in 2020, showcasing its solid standing among competitors. With a focus on providing sustainable solutions and embracing technological advancements, Johnson Controls remains an industry leader. One notable achievement for the company was the acquisition of Tyco International in 2016. This merger significantly strengthened Johnson Controls' position in the fire and security solutions market. As of the latest information available, Johnson Controls continues to innovate in the fields of smart buildings and energy efficiency. The company aims to lead the transition towards a more sustainable and interconnected world. By leveraging advanced technologies and strategic partnerships, Johnson Controls strives to deliver solutions that enhance the comfort, safety, and efficiency of buildings and vehicles. In conclusion, Johnson Controls is a global leader in building efficiency and automotive solutions. With a rich history and a wide range of products and services, the company has established itself as a prominent player in the industry. As it continues to invest in innovation and sustainability, Johnson Controls remains poised for growth and further expansion in the future.

Johnson Controls

Johnson Controls Icon

We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people.

Heavy Industry and Engineering

Chemical Industry

Sanofi Sans

Sanofi, headquartered in Paris, France, is a global pharmaceutical company that specializes in research, development, manufacturing, and marketing of innovative healthcare products. Founded in 1973, Sanofi has a rich history that spans over a century, dating back to the establishment of its predecessors. The company's headquarters, known as the Sanofi Campus, is located in Paris, France. The spacious campus, covering an area of 241,000 square meters, serves as a hub for the company's administrative, research, and development activities. It houses state-of-the-art laboratories, manufacturing facilities, and office spaces. Sanofi operates in multiple therapeutic areas, offering a wide range of pharmaceutical products and services. It focuses on finding solutions for prevalent diseases such as diabetes, cardiovascular diseases, rare diseases, multiple sclerosis, and cancer. Additionally, the company provides vaccines, consumer healthcare products, and innovative solutions in areas like digital health and emerging markets. With a strong global presence, Sanofi operates through a network of subsidiaries, joint ventures, and partnerships. Noteworthy subsidiaries include Genzyme, a leading biotechnology company acquired by Sanofi in 2011, and Sanofi Pasteur, the vaccines division of the company. Sanofi also has extensive joint ventures and partnerships with various organizations around the world, allowing it to expand its reach and collaborative efforts in research and development. Sanofi has established itself as one of the top pharmaceutical companies globally. It consistently ranks among the industry leaders in terms of revenue and market capitalization. In terms of global sales, Sanofi generated revenues of €36.1 billion in 2020, further solidifying its position as one of the largest pharmaceutical companies worldwide. The company has achieved significant milestones and made notable strategic moves in recent years. In 2021, Sanofi announced a strategic shift towards becoming a leader in immunology and rare diseases. This involves focusing on developing breakthrough therapies, expanding research and development efforts, and pursuing targeted acquisitions and partnerships. As of the latest updates, Sanofi continues to pursue its growth strategy by investing in research and development, exploring innovative collaborations, and expanding its product portfolio. The company remains dedicated to addressing global health challenges and improving the lives of patients worldwide through its cutting-edge healthcare solutions.

Sanofi

Sanofi Icon

Sanofi Logo

Vice President in Biologics & Neuroscience IP at Ipsen, boasting experience from Harvard to Tyco. Expert in patents, biotech, and medical devices.

Brad Salcedo

Legal

Licensing

Patent Strategy

Biotechnology

Trademark Law

Commercialization

Competitive Intelligence

Contract Negotiation

Technology Transfer

Senior Counsel

Farming

Biopharmaceuticals

Smart Building

Health Diagnostics

Pharmaceuticals

Due Diligence

Medical Devices

Mergers & Acquisitions

Negotiation

Intellectual Property Management

Joint Venture

Life Science

Litigation

Patent Preparation

Patent Prosecution

Intellectual Property

Startups

Strategic Planning

Business Strategy

Managing Partner

Diagnostics

Patent Drafting

Patentability

Patent Litigation

Legal Assistance

Molecular Diagnostics

Vice President, Biologics and Neuroscience IP at Ipsen

Syngenta Wordmark

F. Brad Salcedo, Esq. - Ipsen | LinkedIn Banner

<p>I’ve supported industry leaders including Ipsen Pharmaceuticals, bioMérieux, Genzyme, Syngenta… · Experience: Ipsen · Location: Hyannis · 500+ connections on LinkedIn. View F. Brad Salcedo, Esq.’s profile on LinkedIn, a professional community of 1 billion members.</p>

F. Brad Salcedo, Esq. - Ipsen | LinkedIn

Brad Salcedo | Fractional Senior Counsel

Brad S.

Empowering Innovation with Strategic IP Leadership

Work

F. Brad Salcedo, Esq. - Ipsen | LinkedIn

Experience

Ipsen

bioMerieux

Syngenta Biotechnology, Inc.

Gosz & Partners, LLP

Tyco International

Genzyme

Brad S.

Empowering Innovation with Strategic IP Leadership

Work

F. Brad Salcedo, Esq. - Ipsen | LinkedIn

Experience

Ipsen

bioMerieux

Syngenta Biotechnology, Inc.

Gosz & Partners, LLP

Tyco International

Genzyme

Similar Members